118 related articles for article (PubMed ID: 18077770)
1. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma.
Yeung J; Chang H
J Clin Pathol; 2008 Jul; 61(7):832-6. PubMed ID: 18077770
[TBL] [Abstract][Full Text] [Related]
2. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
3. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of chromosomal aberrations in multiple myeloma.
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
J Intern Med; 2011 Feb; 269(2):137-47. PubMed ID: 21158983
[TBL] [Abstract][Full Text] [Related]
6. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
7. [Genetic markers as prognostic factors in multiple myeloma].
Conte L G; Braggio E; Figueroa G; Fonseca R
Rev Med Chil; 2009 Apr; 137(4):552-8. PubMed ID: 19623423
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
12. MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients.
Stralen E; Leguit RJ; Begthel H; Michaux L; Buijs A; Lemmens H; Scheiff JM; Doyen C; Pierre P; Forget F; Clevers HC; Bast B
Leukemia; 2009 Apr; 23(4):801-3. PubMed ID: 18830254
[No Abstract] [Full Text] [Related]
13. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
14. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.
Inagaki A; Tajima E; Uranishi M; Totani H; Asao Y; Ogura H; Masaki A; Yoshida T; Mori F; Ito A; Yano H; Ri M; Kayukawa S; Kataoka T; Kusumoto S; Ishida T; Hayami Y; Hanamura I; Komatsu H; Inagaki H; Matsuda Y; Ueda R; Iida S
Leuk Res; 2013 Dec; 37(12):1648-55. PubMed ID: 24210217
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis.
Pruneri G; Alietti A; Agnelli L; Morabito F; Laszlo D; Calabrese L; Fabris S; Bertolini F; Agazzi A; Bottiglieri L; Raviele PR; Baldini L; Pileri S; Sabattini E; Bosari S; Maisonneuve P; Lambertenghi-Deliliers G; Bertoni F; Martinelli G; Viale G; Neri A
Leuk Res; 2008 Oct; 32(10):1628-32. PubMed ID: 18355918
[No Abstract] [Full Text] [Related]
16. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
17. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
[TBL] [Abstract][Full Text] [Related]
18. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
[TBL] [Abstract][Full Text] [Related]
20. [Classification and genetic abnormalities of multiple myeloma].
Hanamura I; Iida S
Nihon Rinsho; 2015 Jan; 73(1):17-27. PubMed ID: 25626298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
